Paraganglioma Clinical Trials in Bethesda, Maryland
5 recruitingBethesda, Maryland
Showing 1–5 of 5 trials
Recruiting
Phase 1
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Kidney CancersHead and Neck TumorsSmall Cell Lung Cancers+3 more
National Cancer Institute (NCI)120 enrolled1 locationNCT06479811
Recruiting
Phase 2
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting
Phase 2
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Neuroendocrine TumorsParagangliomaPheochromocytoma+1 more
National Cancer Institute (NCI)130 enrolled1 locationNCT03206060
Recruiting
Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC322 enrolled84 locationsNCT04924075
Recruiting
Phase 1Phase 2
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
PheochromocytomaGastrointestinal Neuroendocrine TumorsSomatostatin Receptor Positive+1 more
National Cancer Institute (NCI)66 enrolled1 locationNCT06427798